Notice of GM

RNS Number : 8394S

MGC Pharmaceuticals Limited

19 March 2021

 

19 March2021 ASX Code: MXC LSE Code: MXC

MGC Pharmaceuticals Ltd MGC Pharma General Meeting Information and Webinar

MGC Pharmaceuticals Ltd (ASX: MXC, LSE: MXC, 'MGC Pharma' or 'the Company'),   is pleased to announce it will be hosting the General Meeting (GM) webinar for the shareholder meeting to be held at 1202 Hay Street West Perth on Wednesday 31 March 2021 at 4.00pm AWST.

The formal business of the GM will be hosted by MGC Pharma's Chairman, Brett Mitchell with other Board members attending remotely as panellists.

To register for the webinar, please use the link below:

https://us02web.zoom.us/webinar/register/WN_8cwaHl8jSs6PMr4hXi3NyQ  

Upon registration to the webinar participants are welcome to submit questions to the Company.  The Board will endeavour to answer as many questions as possible regarding the Company's operations and future plans at the meeting. Shareholders are strongly encouraged to vote by lodging the proxy form mailed or emailed out to them.

The simplest way to lodge your proxy vote is online, shareholders can follow the below steps for online lodgement:

· Go to www.investorvote.com.au

· Enter the 6-digit control number: 185009

· You will then need your HIN/SRN and postcode to log-on

--Ends--

Authorised for release by the Board, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian [phone] [e-mail] Tim Pearson [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [e-mail] Zoe Alexander [e-mail] [phone]	Australian PR/IR Advisors - Media & Capital Partners Rod Hinchcliffe (IR) [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels :

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

NOGDKCBQABKKKND